AstraZeneca Completes $1B Amolyt Pharma Takeover
AstraZeneca said Monday that it has successfully completed the approximately $1.05 billion acquisition of clinical stage biotechnology company Amolyt Pharma, which was guided by Freshfields, Jones Day and Cooley LLP, weeks after...To view the full article, register now.
Already a subscriber? Click here to view full article